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SUMMARY
Sigma-1 receptors (Sig-1Rs) are integral ER mem-
brane proteins. They bind diverse ligands, including
psychoactive drugs, and regulate many signaling
proteins, including the inositol 1,4,5-trisphosphate
receptors (IP3Rs) that release Ca
2+ from the ER. The
endogenous ligands of Sig-1Rs are unknown. Phos-
pholipase D (PLD) cleaves phosphatidylcholine to
choline and phosphatidic acid (PA), with PA assumed
to mediate all downstream signaling. We show that
choline is also an intracellular messenger. Choline
binds to Sig-1Rs, it mimics other Sig-1R agonists by
potentiating Ca2+ signals evoked by IP3Rs, and it is
deactivated by metabolism. Receptors, by stimu-
lating PLC and PLD, deliver two signals to IP3Rs: IP3
activates IP3Rs, and choline potentiates their activity
through Sig-1Rs. Choline is also produced at synap-
ses by degradation of acetylcholine. Choline uptake
by transporters activates Sig-1Rs and potentiates
Ca2+ signals. We conclude that choline is an endoge-
nous agonist of Sig-1Rs linking extracellular stimuli,
and perhaps synaptic activity, to Ca2+ signals.
INTRODUCTION
The Sigma-1 receptor (Sig-1R) is a small integral membrane pro-
tein expressed mainly in the endoplasmic reticulum (ER) and
concentrated at the dynamic contacts between mitochondria
and ER, the mitochondria-associated ER membrane domains
(MAMs) (Schmidt et al., 2016; Smith and Su, 2017; Su et al.,
2016). Sig-1R was thought to have two transmembrane domains
(TMDs), with its N and C termini in the ER lumen (Aydar et al.,
2002; Hayashi and Su, 2007). This topology was consistent
with evidence that BiP, an ER luminal chaperone protein, binds
to theC-terminal domain of Sig-1R (Hayashi and Su, 2007). How-
ever, a crystal structure of Sig-1R challenges these observations
because it identified only a single TMD within each subunit of a
trimeric complex, and it placed the C-terminal region on the
cytosolic side of the ER membrane (Alon et al., 2017; Schmidt
et al., 2016).
Sig-1Rs are abundant in brain, but they are also expressed in
other tissues (Smith and Su, 2017). They are implicated in many
pathologies, including depression, anxiety, amyotrophic lateral
sclerosis and other neurodegenerative diseases, drug addiction,
neuropathic pain, and cancers (Gueguinou et al., 2017; Su et al.,
2016; Watanabe et al., 2016). Sig-1Rs bind an unusually diverse
array of ligands, most of which are amines. These include antide-
pressants (e.g., fluoxetine), antipsychotics (e.g., haloperidol),
and drugs of abuse (e.g., cocaine and methamphetamine)
(Maurice and Su, 2009;Walker et al., 1990). Sig-1Rs also interact
with many different signaling proteins. Within the ER, these
proteins include inositol 1,4,5-trisphosphate receptors (IP3Rs)
(Hayashi and Su, 2007) and STIM1, the Ca2+ sensor for store-
operated Ca2+ entry (Srivats et al., 2016). At the plasma mem-
brane (PM), Sig-1Rs regulate a variety of receptors and ion
channels (Su et al., 2016).
Althoughmany ligands of Sig-1Rs have opposing effects, their
diversity and the many proteins that interact with Sig-1Rs
confound attempts to classify ligands consistently as agonists
or antagonists across all bioassays (Schmidt et al., 2016; Yano
et al., 2018). A more fundamental distinction may be whether
ligands stabilize oligomeric (antagonists) or monomeric forms
(agonists) of Sig-1R (Gromek et al., 2014; Mishra et al., 2015;
Ossa et al., 2017; Schmidt et al., 2016; Yano et al., 2018). Hence,
agonists by releasing Sig-1Rs from large oligomeric complexes
may free Sig-1Rs to interact with client proteins (Figure 1A).
Several endogenous molecules, including steroids (Monnet
and Maurice, 2006) (notably progesterone), various sphingoli-
pids (Ramachandran et al., 2009), and N,N-dimethyltryptamine
(DMT) (Fontanilla et al., 2009), bind to Sig-1Rs and regulate
some of their activities. It is unclear whether any of these ligands
mediate endogenous regulation of Sig-1Rs, and none has been
shown to link extracellular stimuli to regulation of Sig-1Rs.
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Many extracellular stimuli evoke increases in the intracellular
free [Ca2+] ([Ca2+]i) through receptors that stimulate phospholi-
pase C (PLC), leading to formation of IP3 and release of Ca
2+
from the ER through IP3Rs. Sig-1Rs have been reported to
both potentiate the Ca2+ signals evoked by these receptors by
increasing the IP3 sensitivity of IP3Rs (Hayashi et al., 2000;
Hong et al., 2004; Wu and Bowen, 2008) and to increase the ef-
ficiency of Ca2+ transfer from ER to mitochondria through IP3Rs
(Hayashi and Su, 2007; Shioda et al., 2012).
Here, we demonstrate that agonists of G-protein-coupled re-
ceptors (GPCRs) that stimulate PLC and an increase in [Ca2+]i,
also stimulate phospholipase D (PLD).We show that choline pro-
duced by PLD is an endogenous agonist of Sig-1Rs, and that it
thereby potentiates Ca2+ signals evoked by IP3Rs. Each of the
immediate products of choline metabolism, phosphocholine,
acetylcholine, and betaine, is inactive. Hence, GPCRs signal to
IP3Rs through two parallel pathways that converge to provide
coincident stimulation of IP3Rs. In addition, choline uptake by
specific transporters allows extracellular choline to stimulate
Sig-1Rs and potentiate IP3-evoked Ca
2+ signals. We conclude
that choline is an endogenous agonist of Sig-1Rs that links
both cell signaling pathways (through PLD) and the activity of
cholinergic synapses (through choline uptake) to regulation of
IP3-evoked Ca
2+ signals.
RESULTS
Choline Binds to Sig-1Rs and Potentiates IP3-Evoked
Ca2+ Signals
Most high-affinity ligands of Sig-1Rs comprise a tertiary amine
flanked by a short acyl chain and hydrophobic moieties (Glen-
non, 2005; Ossa et al., 2017). Endogenous agonists are unlikely
to have such high affinity because they must rapidly associate
with and dissociate from Sig-1Rs if they are to acutely regulate
them. We considered whether choline, a quaternary amine with
an acyl chain but no hydrophobic moieties, might be an endog-
enous agonist of Sig-1Rs.
(+)-Pentazocine is a high-affinity, selective ligand of Sig-1Rs
(equilibrium dissociation constant, Kd = 5.5 nM) (de Costa et al.,
1989). Specific binding of [3H](+)-pentazocine tomembranes pre-
pared from Neuro-2A cells stably expressing Sig-1R was
completely displaced by choline (Ki = 525 mM; pKi = 3.28 ± 0.16;
h = 1.07 ± 0.2; mean ± SEM; n = 5; where pKi is the negative log
of the Kd, and h is the Hill coefficient) (Figure 1B). Phosphocholine,
the major product of choline metabolism in most cells (Figure 1C)
(Corbin and Zeisel, 2012), did not displace specific [3H](+)-pentaz-
ocine from Sig-1Rs, and the other immediate products of choline
metabolism, betaine (Ki = 1.32 mM; pKi = 2.88 ± 0.23; h = 1.40 ±
0.35; n = 5) and acetylcholine (Ki 12 mM; n = 5), were less
Figure 1. Choline Is an Agonist of Sig-1Rs
(A) Clusters of Sig-1Rs anchored at MAMs are
thought to dissociate into monomers when they
bind a Sig-1R agonist, freeing Sig-1Rs to interact
with their targets, within and beyond MAMs. The
targets include IP3Rs.
(B) Specific binding of [3H](+)-pentazocine (5 nM)
in the presence of choline and related compounds
using membranes from Neuro-2A cells stably
expressing Sig-1R-GFP (mean ± SEM; n = 5,
with 3 replicates for each). Specific binding of
3H-pentazocine was 90% ± 3% of total binding
(mean ± SEM; n = 3) for membranes from
cells overexpressing Sig-1R, and 13% ± 5% for
mock-transfected cells.
(C) Choline metabolism (structures from http://
www.hmdb.ca).
(D) NG108-15 cells were incubated (2 hr, 37C)
with PRE-084 (25 mM) or BD1047 (25 mM), and
then, in the continuous presence of the Sig-1R
ligands, loaded with Fluo-8 by incubation with
Fluo-8 AM in HEPES-buffered saline (HBS)
(30 min, 20C, with a further 30 min to allow de-
esterification of Fluo-8). BAPTA (2.5 mM) was then
added to chelate extracellular Ca2+ before addi-
tion of bradykinin (10 mM). Results show typical
responses as means of 3 replicates.
(E) Summary results (mean ± SEM; n = 5, each
with 3 replicates) show peak increases in [Ca2+]i
(D[Ca2+]i) evoked by bradykinin. *p < 0.05 for
maximal responses relative to control, one-way
ANOVA with Dunnett’s test.
(F) Pooled results (mean ± SEM; n = 20; as per-
centages of matched control response) for all
bradykinin concentrations. The asterisk (*) de-
notes 95% confidence intervals that exclude
100%.
See also Figure S1A.
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effective than choline. This is consistent with choline binding with
greater affinity than its metabolites to the same site as known ag-
onists and antagonists of Sig-1Rs.
Subsequent experiments explore the interactions of choline
with Sig-1Rs in NG108-15 cells. These neuroblastoma-glioma
hybrid cells retain many properties of neurons, including respon-
siveness to neurotransmitters, and the ability to synthesize and
release acetylcholine (Hamprecht et al., 1985); they express
endogenous Sig-1Rs, and their bradykinin receptors stimulate
PLC and Ca2+ release from the ER through IP3Rs (Fig-
ure S1A). The bradykinin-evoked Ca2+ signals were enhanced
by pre-incubation with a Sig-1R agonist (PRE-084) and attenu-
Figure 2. Choline Potentiates IP3-Evoked
Ca2+ Release by Stimulating Sig-1Rs
(A) Ca2+ signals recorded from Fura-2-loaded
NG108-15 cells after microinjection (1% cell
volume) of IP3 (pipette concentration, 0.5 mM),
(+)SKF-10047 (SKF, 100 mM), or choline (100 mM).
Results (n = 6 cells) show untransfected cells or
after transfection with scrambled shRNA or Sig-1R
shRNA, each tagged with red fluorescent protein
(RFP).
(B) Summary (mean ± SD; n = 6) shows peak
[Ca2+]i. *p < 0.05, ANOVA with Bonferroni test,
relative to matched stimuli in untransfected cells.
The effects of pre-incubating cells with BD1047
(25 mM, 15 min) are also shown.
(C) Similar analysis of the effects of microinjected
IP3 (pipette concentration, 0.5 mM) or acetylcho-
line, betaine, or phosphocholine (pipette concen-
tration, 100 mM for each), alone or in combination.
(D) Summary (mean ± SD; n = 6) shows peak
[Ca2+]i. *p < 0.05, ANOVA with Bonferroni test,
relative to IP3 alone.
(E) Western blot (WB) of Sig-1R after transfection
of NG108-15 cells with scrambled or Sig-1R
shRNA, each tagged with RFP. Tagged shRNAs
were used to allow identification of transfected
cells in microinjection experiments. Hence, WB
from cell populations probably over-estimates
Sig-1R expression in functional analyses of micro-
injected cells treated with Sig-1R shRNA. Sig-1R
expression was reduced to 50% ± 12% of control
levels by the shRNA treatment (mean ± SD; n = 3).
(F)WB showing detectable expression of Sig-1R in
MCF7 cells only after transfection with Sig-1R-
GFP. Typical of 4 blots. Mr markers (kDa) are
shown.
(G) Ca2+ signals recorded from Fura-2-loaded
MCF7 cells after microinjection as described for
(C). Results (n = 6 cells) are from control cells or
after transfection with GFP or Sig-1R-GFP.
(H) Summary (mean ± SD; n = 6) results show
[DCa2+]i. *p < 0.05 for maximal responses relative
to matched untransfected cells, one-way ANOVA
with Dunnett’s test.
See also Figures S1B and S1C.
ated by an antagonist (BD1047) (Figures
1D–1F). Microinjection of NG108-15 cells
with IP3 evoked a transient increase in
[Ca2+]i, whereas microinjection of choline
or the Sig-1R agonist, (+)SKF-10047, had no effect. However,
co-injection of choline or (+)SKF-10047 with IP3 potentiated
the IP3-evoked Ca
2+ signals (Figures 2A and 2B). When applied
to intact cells, neither choline nor other Sig-1R ligands signifi-
cantly affected the Ca2+ content of the intracellular stores (Fig-
ures S1B and S1C). The potentiation of IP3-evoked Ca
2+ release
by choline was blocked by pre-incubation with the Sig-1R antag-
onist, BD1047 (Figure 2B). Neither betaine, phosphocholine,
nor acetylcholine mimicked the effects of microinjected choline
(Figures 2C and 2D).
Treatment of NG108-15 cells with appropriate short hairpin
RNA (shRNA) reduced expression of Sig-1R (Figure 2E) and
332 Cell Reports 26, 330–337, January 8, 2019
abolished the potentiating effects of choline and (+)SKF-10047,
without affecting responses to IP3 alone (Figures 2A and 2B).
In MCF7 breast cancer cells, Sig-1R expression was scarcely
detectable (Figure 2F) (Wu and Bowen, 2008). In these cells,
neither microinjected choline nor (+)SKF-10047 potentiated
IP3-evoked Ca
2+ signals, but the signals were potentiated after
expression of Sig-1R-GFP (Figures 2F–2H). These results estab-
lish that choline, by activating Sig-1Rs, potentiates IP3-evoked
Ca2+ release.
Sig-1Rs Contribute to Ca2+ Signals Evoked by GPCRs
Extracellular ATP stimulates PLC through P2Y6 receptors in
NG108-15 cells (Sak et al., 2001). Loss of Sig-1Rs in NG108-
Figure 3. Sig-1R and PLD Contribute to
Ca2+ Signals Evoked by Agonists of GPCRs
(A) Typical pseudocolor images show peak Ca2+
signals (F340/F380) evoked by ATP (50 mM) in Fura-
2-loaded NG108-15 cells transfected with control
shRNA or shRNA to PLD1 and PLD2, or Sig-1R,
each taggedwith RFP. Calibration code (F340/F380)
and scale bar (20 mm) apply to all panels.
(B) Time course of response to ATP (bar; n = 6).
(C) Summary (mean ± SD; n = 6) shows D[Ca2+]i
evoked by ATP. *p < 0.05, ANOVA with Bonferroni
test, relative to untransfected cells.
(D) D[Ca2+]i evoked by bradykinin in populations of
NG108-15 cells. Histogram (which shares the y
axis) compares responses to bradykinin (10 mM)
after treatment with scrambled or Sig-1R shRNA.
Results are means ± SEM; n = 3 with duplicate
determinations. *p < 0.05, Student’s t test.
(E) WB shows effects of indicated shRNA, each
tagged with RFP, on expression of PLD1 and
PLD2 in NG108-15 cells. Mr markers (kDa) are
shown. Results, typical of 3 WBs, underestimate
knockdowns in the cells used for Ca2+ measure-
ments, which used only cells shown to be trans-
fected by expression of RFP (see A).
(F and G) Intracellular concentrations of choline (F)
and IP3 (G) during stimulation of NG108-15 cells
with ATP (50 mM, bar) show the effects of shRNA
for PLD1 and PLD2. Results show means ± SD;
n = 6.
(H) GPCRs that activate PLC and phospholipase D
(PLD) initiate two parallel signaling pathways that
converge at IP3Rs. IP3 from PLC directly activates
IP3R. Choline from PLD activates Sig-1R, which
potentiates IP3-evoked Ca
2+ release.
15 cells (by shRNA) reduced the ampli-
tude of the Ca2+ signals evoked by maxi-
mally effective concentrations of ATP
(Figures 3A–3C) or bradykinin (Figure 3D).
We next considered whether the contri-
bution of Sig-1Rs to the Ca2+ signals
evoked by GPCRs might be mediated
by choline. Both mammalian isoforms of
PLD (PLD1 and PLD2) are almost ubiqui-
tously expressed enzymes that hydrolyse
phosphatidylcholine (PC) to phosphatidic
acid (PA) and choline. PLDs are regulated
by many signals, including those that stimulate PLC and protein
kinase C (PKC) (Selvy et al., 2011).
The basal choline concentration in NG108-15 cells
(144 ± 7 mM) was similar to values reported for other cells
(100–400 mM) (Pelech and Vance, 1984). Stimulation of
NG108-15 cells with extracellular ATP increased the intracel-
lular concentrations of both choline and IP3. Knockdown of
PLD1 and PLD2 expression using shRNA (Figure 3E) pre-
vented the increase in choline concentration without affecting
IP3 production (Figures 3F and 3G). Furthermore, the ATP-
evoked Ca2+ signals were similarly and substantially attenu-
ated by loss of Sig-1R or loss of PLDs (Figures 3A–3C). The
results so far demonstrate that GPCRs, by stimulating both
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PLC and PLD, generate parallel signals, IP3 and choline,
which converge to stimulate Ca2+ release through IP3Rs
(Figure 3H).
Choline Uptake Regulates Ca2+ Signals
Synthesis of acetylcholine within cholinergic nerve terminals
requires choline uptake by a high-affinity, Na+-dependent
transporter (CHT1 [choline high-affinity transporter 1]) ex-
pressed mostly at cholinergic terminals (Haga, 2014; Sarter
and Parikh, 2005). Additional Na+-independent transporters
mediate low-affinity choline uptake (OCTs [organic cation
transporters]); and the widely expressed choline transporter-
like proteins (CTL1-5, encoded by SLC44A1-5) mediate
high-affinity uptake outside cholinergic terminals (Haga,
2014; Machova´ et al., 2009; Yamada et al., 2011). NG108-15
cells are capable of high-affinity choline uptake and they ex-
press CTL1, but not CHT1 (Machova´ et al., 2009), consistent
with evidence that CTL1 is expressed in neurons and glia
(Traiffort et al., 2013).
Incubation of NG108-15 cells with choline caused a time-
dependent increase in the amplitude of the Ca2+ signals
subsequently evoked by bradykinin (Figure 4A). The effect
was minimally affected by removing the extracellular choline
immediately before stimulation with bradykinin (Figure S2),
suggesting that choline potentiates Ca2+ signals after its
transport into cells. Potentiation of bradykinin-evoked Ca2+
signals by extracellular choline was substantially attenuated
by loss of Sig-1R (shRNA) or CTL1 (small interfering RNA
[siRNA]), but unaffected by scrambled shRNA or siRNA (Fig-
ures 4C–4E).
Figure 4. CTL1-Mediated Choline Uptake
Potentiates IP3-Evoked Ca
2+ Signals
(A) NG108-15 cells were incubated in HBS alone
or with 3 mM choline for the indicated times
before adding bradykinin (1 mM) and immediately
recording the increase in [Ca2+]i. Results (mean ±
SEM; n = 3 with duplicate determinations) show
D[Ca2+]i evoked by bradykinin.
(B) Summary results (mean ± SEM; n = 3)
show bradykinin-evoked D[Ca2+]i after incuba-
tion with the indicated choline concentrations
(105 min).
(C) WB showing effects of the indicated siRNA
(for CTL1) or shRNA (for Sig-1R) and their scram-
bled counterparts on expression of CTL1 and
Sig-1R in NG108-15 cells. Mr markers (kDa) are
shown.
(D) Summary results (mean ± SD; n = 5) show
CTL1 expression in cells treated with the indicated
siRNA expressed as a percentage of the matched
cells treated with scrambled siRNA.
(E) Summary results (mean ± SEM; n = 5 plates
with 2 replicates) show the effects of 10 mM
choline on bradykinin-evoked Ca2+ signals.
*p < 0.05, **p < 0.01, one-way ANOVA with Dun-
nett’s test, relative to control (B and E).
(F) Ca2+-mobilizing GPCRs stimulate PLC and
PLD, with consequent formation of IP3 and
choline. Although we have not resolved how
GPCRs stimulate PLD in NG108-15 cells, signals
evoked by both PLC and parallel pathways
are known to stimulate PLD. IP3 stimulates IP3R,
while choline binds to Sig-1Rs, causing them
to potentiate IP3R activity. Metabolism of IP3
and choline terminates their signaling. Hence,
GPCRs regulate IP3Rs through two parallel,
but converging, pathways. Import of extracellular
choline by transporters, including the widely
expressed CTL1, can also deliver choline to
Sig-1Rs.
(G) Acetylcholine (ACh) released at cholinergic
terminals can activate post- and pre-synaptic
receptors, before its rapid hydrolysis to choline
by acetylcholinesterase (AChE). Hence, synaptic
activity is rapidly followed by a substantial local
increase in choline concentration. Transporters (red circles) in the cholinergic terminal (CHT1) and neighboring cells (CTL1-5 and OCT) can import the
choline, which will then stimulate Sig-1Rs, providing cells with a paracrine reporter of recent synaptic activity.
See also Figure S2.
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DISCUSSION
Sig-1Rs respond to many diverse drugs, including some that are
commonly abused or used clinically, but it is unclear whether
endogenous agonists regulate Sig-1Rs (Maurice and Su,
2009). Here, we provide evidence that choline (Figure 1C), best
known as a precursor for synthesis of acetylcholine and PC,
the most abundant membrane phospholipid in mammalian cells,
is an endogenous agonist of Sig-1Rs. We show that choline
meets the three essential criteria of an intracellular messenger,
namely it is produced in response to extracellular stimuli, it exerts
a specific intracellular action, and it is endogenously deacti-
vated. We conclude that choline is an intracellular messenger
linking GPCRs, through Sig-1Rs, to Ca2+ release from intracel-
lular stores (Figure 4F).
Choline mimicked known Sig-1R agonists by competing with
(+)-pentazocine for binding to Sig-1Rs (Figure 1B) and by poten-
tiating the Ca2+ signals evoked by receptors that stimulate IP3
formation (Figures 2A, 2B, and 2D). The immediate metabolites
of choline were ineffective (Figures 2C and 2D). The effect of
choline on Ca2+ signals was attenuated when Sig-1R expression
was reduced (Figures 2A, 2B, and 2E); and in cells without Sig-
1Rs, expression of Sig-1R endowed the cells with sensitivity to
choline (Figures 2F–2H). The Ca2+ signals evoked by GPCRs
that stimulate formation of IP3 were attenuated when Sig-1R
expression was reduced (Figures 3A–3D). ATP, which stimulates
PLC through P2Y6 receptors in NG108-15 cells (Sak et al., 2001),
rapidly evoked formation of IP3 and choline, but only the latter
required PLDs (Figures 3F and 3G). Furthermore, the ATP-
evoked Ca2+ signals were similarly attenuated by loss of PLDs
or Sig-1Rs (Figure 3C). Bradykinin-evoked Ca2+ signals were
likewise attenuated by loss of Sig-1Rs (Figure 3D).
Many GPCRs that stimulate PLC also activate PLD, and most
agonists that activate PLD also stimulate PLC. However, the
links between GPCRs and stimulation of mammalian PLD differ
between cell types, and the stimulatory signals, which include
PKC, Ca2+, small GTPases (rho and ADP-ribosylation factor
[Arf]), phosphatidylinositol 4,5-bisphosphate, and phosphatidyli-
nositol 3,4,5-trisphosphate, can be generated by PLC or parallel
pathways (Exton, 1999; Selvy et al., 2011). Hitherto, signaling
downstream of PLD has been thought to arise entirely, directly
or indirectly, from PA (Selvy et al., 2011). We suggest that the
other product of PLD activity, namely choline, is also an impor-
tant intracellular messenger that regulates Sig-1Rs and thereby
IP3-evoked Ca
2+ release (Figures 3H and 4G). Our estimate of
the intracellular choline concentration in NG108-15 cells after
GPCR activation (900 mM) (Figure 3F) is similar to that required
for binding to Sig-1Rs (Ki = 525 mM) (Figure 1B). The low affinity of
choline, relative to the many ligands used to establish structure-
affinity relationship for Sig-1R (Glennon et al., 1992), is important
because it will allow Sig-1R to respond rapidly to acute changes
in intracellular choline concentration.We conclude that choline is
an endogenous agonist of Sig-1Rs, a consequence of which in-
cludes potentiation of IP3-evoked Ca
2+ release (Figure 3H).
Choline is an essential nutrient that cells import through trans-
porters from plasma, where the choline concentration is typically
5–10 mM, although it varies with diet (Sarter and Parikh, 2005). At
cholinergic synapses, the choline concentration may be much
higher (1 mM) after synaptic activity, when acetylcholine
is rapidly hydrolysed by acetylcholinesterase (Figure 4G). Our
results show that extracellular choline, at concentrations encom-
passing likely synaptic concentrations, potentiates GPCR-
evoked Ca2+ signals. The potentiation requires both Sig1R and
the choline transporter, CTL1 (Figures 4A–4E and S2). These ob-
servations suggest an additional signaling role, whereby
changes in extracellular choline concentration might regulate
Sig-1Rs and thereby Ca2+ signaling. Such a mechanism might
be particularly effective at cholinergic synapses of neuromus-
cular junctions or within the autonomic nervous system (Pic-
ciotto et al., 2012), where rapid transient increases in choline
concentration follow synaptic activity. Choline might then deter-
mine the sensitivity of adjacent neurons or glia to PLC-coupled
GPCRs (Figure 4G), consistent with many reported interactions
between Sig-1Rs and cholinergic transmission (van Waarde
et al., 2011). Hence, choline, as an endogenous agonist of Sig-
1Rs, may be both an intracellular messenger linking GPCRs
through PLD to Sig-1Rs (Figure 4F); and a paracrine signal at
cholinergic synapses linking synaptic activity, through choline
transporters, to Sig-1R regulation in nearby cells (Figure 4G).
We conclude that choline is an endogenous agonist of Sig-
1Rs. Although we examined the consequences of activating
Sig-1Rs only in the context of IP3-evoked Ca
2+ signals, it is likely
that choline, like other agonists of Sig-1Rs, also promotes inter-
action of Sig-1Rs with other signaling proteins. We propose that
choline may be delivered to Sig-1Rs as a paracrine reporter of
activity at cholinergic synapses through choline transporters,
or as an intracellular messenger from PLD activated by GPCRs
(Figures 4F and 4G). The GPCRs that stimulate both PLC and
PLD thereby send parallel signals to IP3Rs: IP3 directly activates
IP3Rs, while choline stimulates Sig-1Rs, which potentiate IP3R
activity. IP3Rs thereby function as coincidence detectors, inte-
grating signals from IP3 and Sig-1Rs (Figures 3G and 4F).
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BAPTA Molekula, Dorset, UK Cat# 20358510
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Fura-2 AM AAT Bioquest Cat# 21020
ThermoFisher Cat# F1221
G-418 ThermoFisher Cat# 10131027
Glucose ThermoFisher Cat# 10141520
Haloperidol Sigma-Aldrich Cat# H1512
Hank’s balanced salt solution (HBSS) ThermoFisher Cat# 21-023-CV
HEPES Merck Millipore Cat# 391338
Ionomycin Apollo Scientific, Stockport, UK Cat# 56092-81-0
Lipofectamine ThermoFisher Cat# 18324012
Lipofectamine RNAiMax ThermoFisher Cat# 13778150
Odyssey blocking buffer LI-COR Cat# 927-50000
Opti-MEM I ThermoFisher Cat# 11058-021
[3H]-(+)-Pentazocine (26.9 Ci/mmol) Perkin-Elmer, Richmond, CA Cat# NET10560250UC
PRE-084 hydrochloride Tocris Cat# 0589
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TurboFectin 8.0 OriGene Cat# TF81001
Tris base ThermoFisher Cat# BP152-1
Triton X-100 Sigma-Aldrich Cat# T8787
Tween-20 Sigma-Aldrich Cat# T5927
Critical Commercial Assays
BCA protein assay kit (Pierce) ThermoFisher Cat# 23225
Choline assay kit BioVision, Mountain View, CA Cat# K615-100
IP3 assay kit DiscoveRx, Fremont, CA Cat# 90-0037
Experimental Models: Cell Lines
NG108-15 cells American Type Culture Collection
(ATCC), Manassas, VA
Cat# ATCC HB-12317
MCF7 cells ATCC Cat# ATCC HTB-22
Neuro-2A cells ATCC Cat# ATCC CCL-131
Recombinant DNA
Human Sig-1R-GFP in pCMV6-AC-GFP OriGene Cat# RG201206
RFP-tagged shRNA (HuSH, 29-mer shRNA in
pRFP-C-RS) against human Sig-1R [GAGTAT
GTGCTGCTCTTCGGCACCGCCTT]
OriGene Cat# TF311012
FI344041
RFP-tagged shRNA (HuSH, 29-mer shRNA in
pRFP-C-RS) against rat PLD1 [GCCTCTATCG
CCAACTTCACCGCCGTAAT]
OriGene Cat# TF711124
FI744500
RFP-tagged shRNA (HuSH, 29-mer shRNA in
pRFP-C-RS) against rat PLD2 [GGAGACTGG
ACATTATGCTCAAGAGGAAG]
OriGene Cat# TF711696
FI746786
RFP-tagged scrambled shRNA (HuSH, 29-mer
scrambled shRNA in pRFP-C-RS)
OriGene Cat# TF311012
TR30015
Silencer siRNA (3 different 21-bp siRNA) against
rat CTL1 (SLC44A1)
ThermoFisher Cat# 192756
Cat# 192757
Cat# 55087
Control Silencer siRNA ThermoFisher Cat# AM4611
Software and Algorithms
Prism 5, version 5 GraphPad, La Jolla https://www.graphpad.com/
GeneTools, version 4 Syngene, Cambridge, UK https://www.syngene.com/
Odyssey, version 3 LI-COR https://www.licor.com/
SoftMax Pro, version 7 Molecular Devices, San Jose, CA https://www.moleculardevices.com/
NIS-Elements AR 3.1 Nikon, Melville, NY https://www.nikon.com/
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
The NG108-15 cell line (ATCC) is a somatic hybrid derived from amouse neuroblastoma and rat glioma. NG108-15 cells were grown
in DMEM/F12 with 10% fetal bovine serum (FBS). MCF7 cells (ATCC) were derived from a humanmetastatic mammary tumor. These
cells were grown in RPMI with 10% FBS. Neuro-2A cells (ATCC), which were used only for heterologous expression of Sig-1R-GFP
for radioligand binding analyses, were derived from a mouse neuroblastoma. Neuro-2A cells were grown in DMEM containing 10%
FBS, and further supplemented with G-418 (100 mg/mL) for the cells stably expressing Sig-1R-GFP. We have not established the sex
of the animals from which NG108-15 and Neuro-2A cells were derived. All cells were grown in humidified air at 37C with 5% CO2.
Cells were passaged when they reached around 80% confluence. The authenticity of the cell lines was not confirmed, but screening
established that all cells were free of mycoplasma.
METHOD DETAILS
Transfection of Cells
Cells were transiently transfected using either TurboFectin 8.0 or electroporation. For the former, plasmid DNA was added to
TurboFectin 8.0 in OptiMEM I (TurboFectin:DNA, 3:1), incubated (15-30 min, 20C), and the complex was then added to cells in
6-well plates (1-1.5 mg DNA/well) in complete medium, and incubated for 24-48 h. For electroporation, cells (80%–90% confluent
in a T75 flask) were scraped into culture medium, centrifuged (150 xg, 5 min), and resuspended in Opti-MEM I (2 3 106 cells/mL).
Cells (500 mL) were transferred to electroporation cuvettes (800 mL, 4-mm gap; Eppendorf, Hamburg, Germany) with plasmid
DNA (5-10 mg/cuvette) and the cells were subjected to electroporation using a GenePulser Xcell (BioRad, 200-250V, 700-900 mF,
18-20 ms). Transfected cells were plated in Opti-MEM I in 6-well plates, FBS (10%) was added after 4 h, and the medium was
replaced after 24 h.
Neuro-2A cells stably expressing Sig-1R-GFP were generated by transfecting cells with plasmid encoding human Sig-1R-GFP
using Lipofectamine. Cells were grown in medium containing G418 (400 mg/mL), and after 2 weeks resistant colonies were selected
and propagated. Stable cell lines with intermediate levels of Sig-1R-GFP expression (determined by fluorescence microscopy) were
identified and then maintained in DMEM supplemented with FCS (10%) and G418 (100 mg/mL).
For expression of human Sig-1R-GFP, cells grown in 6-well plates were transfected with 1-1.5 mg DNA/well. To reduce expression
of Sig-1R or PLDs, RFP-tagged shRNA constructs were used. Each set of constructs included four different 29-mer targeting shRNA
in a pRFP-C-RS plasmid. Using methods reported previously (Brailoiu et al., 2016), we used western blotting to assess the ability of
each individual construct to reduce expression of its target protein (Sig-1R, PLD1 or PLD2). Themost effective shRNA construct from
each set was used for the experiments described here. The constructs were used individually for Sig-1R knockdown (2 mg/mL) or as a
pair for knockdown of PLD1 andPLD2 (1 mg/mL of each). The same scrambled RFP-shRNA construct (2 mg/mL) was used as a control
for all shRNA analyses.
Lipofectamine RNAiMax was used to transfect cells simultaneously with three different siRNAs against CTL1 (50 nM of each)
to reduce CTL1 expression. A siRNA with no known target in mammalian genomes (150 nM) was used as a control for the siRNA
experiments (Silencer control, ThermoFisher). Cells were used 24-48 h after transfection.
Radioligand Binding
Membranes were prepared from Neuro-2A cells stably expressing Sig-1R-GFP (Wu and Bowen, 2008). Cells (1.73 108) were har-
vested (500 xg, 5min) in phosphate-buffered saline (PBS) containing EGTA (1mM), homogenized in coldmedium (10mL; 50mMTris-
HCl, 320 mM sucrose, 2 mM EDTA, 5 mMMgCl2, pH 7.4), centrifuged (50,000 xg, 4
C, 10 min), the pellet was then resuspended by
homogenization (2mg protein/mL) in bindingmedium (50mMTris-HCl, 1mMEDTA, 3mMMgCl2, pH 7.4) and stored at80C. Bind-
ing assays (final volume 500 mL) were performed in glass tubes with binding medium containing BSA (5 mg/mL), [3H](+)-pentazocine
(5 nM, 26.9 Ci/mmol), competing ligands and membranes (100 mg). After 1 h at 30C, bound ligand was recovered by rapid filtration
throughWhatman GF/C filters pre-soaked in polyethyleneimine (0.1%, 2 h), the filters were washed twice, and their radioactivity was
determined by liquid scintillation counting. Non-specific binding was determined in the presence of 5 mM haloperidol.
Western Blotting
Lysates were prepared from cells 48 h after transfection. Cells were collected (150 xg, 5 min) and lysed (1 h, 4C) in medium
comprising: NaCl (50 mM), Tris (20 mM), Mg acetate (10 mM), Triton X-100 (1%, v/v), cOmplete protease inhibitor mixture, Na ortho-
vanadate (1 mM) and Na fluoride (5 mM), pH 7.3. After centrifugation (14,000 xg, 15 min), the supernatant was collected and its pro-
tein concentration determined using a BCA assay kit. Cell lysates, which were used immediately or after storage at80C, were sub-
ject to SDS-PAGE using Mini-PROTEAN TGX 4%–20% gels (BioRad, Hercules, CA) or NuPAGE 4%–12% Bis-Tris gels (Invitrogen,
Paisley, UK). Proteins were transferred to Odyssey nitrocellulose membranes (LI-COR Biosciences) or PVDF membranes (iBlot,
Invitrogen). Membranes were washed and blocked (1 h, 20C) with Odyssey blocking buffer or TBST (137 mM NaCl, 20 mM Tris,
0.1% Tween-20, pH 7.6) supplemented with 5% (w/v) BSA. Membranes were incubated (12 h, 4C) with primary antibodies in
TBST and 1% BSA, washed with TBST (3 3 5 min), incubated with secondary antibodies in TBST and 1% BSA (1 h, 20C), and
then washed with TBST. Bands were visualized by infrared emission (LI-COR Infrared Imager, resolution 169 mm, intensity 4.5-6)
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or by incubation with HRP-conjugated secondary antibodies (1 h), followed by washing and detection with ECL Prime. Densitometric
analysis used Odyssey or GeneTools software, or ImageJ (NIH, Bethesda, USA). The antibodies used and their dilutions are listed in
the Key Resources Table.
Microinjection and Analysis of Ca2+ Signals in Single Cells
For measurements of [Ca2+]i in single Fura-2-loaded cells grown on glass coverslips (#1.5, 25-mm diameter, Warner Instruments),
cells were incubated with Fura-2 AM (5 mM, 45 min, 20C) in Hanks’ balanced salt solution (HBSS), washed 3 times, and incubated
for a further 45 min before experiments (Brailoiu et al., 2009). Fluorescence images (alternate excitation at 340 and 380 nm; emission
at 510 nm) were acquired at 0.25 Hz using an inverted Nikon Eclipse Ti microscopewith a Perfect Focus System and aCoolSnap HQ2
CCD camera (Photometrics Scientific). Images were acquired and analyzed using NIS-Elements AR 3.1 software (Nikon). After
correction for background, determined from an area outside the cell, fluorescence ratios (F340/F380) were calibrated to [Ca
2+]i (Gryn-
kiewicz et al., 1985). Injections were performed using Femtotips II, InjectMan N I2 and FemtoJet systems (Eppendorf) (Brailoiu et al.,
2009). Pipettes were back-filled with intracellular solution (110 mM KCl, 10 mM NaCl, 20 mM HEPES, pH 7.2) (Guse et al., 1997) and
appropriate drugs. The injection time was 0.4 s at 60 hPa with a compensation pressure of 20 hPa in order to inject 1% of the cell
volume.
Measurement of Ca2+ Signals in Cell Populations
For measurements of [Ca2+]i in cell populations, confluent cultures of cells in 96-well plates were loaded with Fluo-8 by incubation
with Fluo-8 AM (2 mM, 30 min, 20C) in HEPES-buffered saline (HBS) supplemented with 0.02% pluronic acid. The medium was then
replacedwith HBS, and after 30min at 20C to allow de-esterification of the indicator, fluorescence was recorded using a FlexStation
III plate-reader (MDS Analytical Devices, Wokingham, UK) (Konieczny et al., 2017; Tovey et al., 2006). Fluorescence was captured
and processed using SoftMax Pro software. All measurements were performed in HBS at 20C. HBS comprised: 135 mM NaCl,
5.9 mM KCl, 1.2 mMMgCl2, 1.5 mM CaCl2, 11.5 mM glucose, 11.6 mM HEPES, pH 7.3. Fluorescence was recorded at 1.44 s inter-
vals, with excitation at 485 nm and emission at 525 nm. The minimal (Fmin, Ca
2+-free indicator) and maximal (Fmax, Ca
2+-saturated
indicator) fluorescence values were determined from several parallel wells in each plate after addition of Triton X-100 (0.1%) with
either BAPTA (10 mM, for Fmin) or CaCl2 (10 mM, for Fmax). Fluorescence values (F) were then calibrated to [Ca
2+]i from:

Ca2+

i
=KD3
F Fmin
Fmax  F
The KD of fluo-8 was assumed to be 389 nM.
Measurements of Intracellular IP3 and Choline Concentrations
NG108-15 cells (1010 cells) in HBSS (0.5 mL, 20C) were stimulated with ATP and the reaction was terminated by addition of cold
HClO4 (1 mL, 0.75 M). After centrifugation (2000 3 g, 5 min, 4
C), the supernatant was removed, PBS (270 mL) was added, and
the mixture was sonicated. After centrifugation (15,000 3 g, 10 min), assay kits were used to determine the amounts of choline
(BioVision Inc.) and IP3 (DiscoveRx) in the supernatant, according to the manufacturer’s instructions. A volume of 2.5 pL for an
NG108-15 cell (Rouzaire-Dubois and Dubois, 1997) was used to calculate intracellular concentrations of IP3 and choline.
QUANTIFICATION AND STATISTICAL ANALYSIS
For analyses of radioligand binding results, each equilibrium competition-binding curve was fitted to a logistic equation (GraphPad
Prism, version 5), from which the half-maximal inhibitory concentration (IC50) and Hill coefficient (h) were determined. The IC50 value,
[3H](+)-pentazocine concentration (5 nM) and Kd of (+)pentazocine for Sig-1R (5.5 nM) (de Costa et al., 1989) were used to calculate Ki
values (Ki is the Kd determined by equilibrium competition binding) (Cheng and Prusoff, 1973). The negative logarithms of these
individual Ki values (pKi) were pooled for statistical analysis. All results are presented as means ± SD or SEM, as appropriate,
from n independent analyses. ANOVA, followed by Dunnett’s, Bonferroni or Tukey tests, was used to evaluate differences between
groups (GraphPad Prism, version 5). p < 0.05 was considered significant. The tests used are reported in the figure legends.
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